AU Patent

AU2022253474A1 — Compounds and methods for theranostic targeting of parp activity

Assigned to University of Texas System · Expires 2023-11-16 · 3y expired

What this patent protects

The synthesis and use of radiolabeled derivatives of poly-(ADP-ribose) (PARP) inhibitors in positron emission tomography (PET) imaging methods are disclosed. A novel non-radioactive analogue of the PARP inhibitor Talazoparib (TZ) provides a branch point for the syntheses of vario…

USPTO Abstract

The synthesis and use of radiolabeled derivatives of poly-(ADP-ribose) (PARP) inhibitors in positron emission tomography (PET) imaging methods are disclosed. A novel non-radioactive analogue of the PARP inhibitor Talazoparib (TZ) provides a branch point for the syntheses of various radiolabeled Talazoparib derivatives. Aspects of the disclosure include such radiolabeled derivatives and TZ analogues, along with methods of use for diagnosis, treatment, imaging, and theranosis of cancer.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022253474A1
Jurisdiction
AU
Classification
—
Expires
2023-11-16
Drug substance claim
No
Drug product claim
No
Assignee
University of Texas System
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.